Evidence map›Paper›PMID 7489845›Full record

Trial reportDiabetologia1995

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.

K S Lam, I K Cheng, E D Janus, R W Pang

Open access · bronzeAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 7 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 7 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Normoalbuminuric diabetic kidney disease.Frontiers of medicine · 2017
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Lipids and diabetic nephropathy.Current diabetes reports · 2006
    Review
  17. Lipids and diabetic renal disease.Current diabetes reports · 2005
    Review
  18. Review
  19. Review
  20. The reno-protective role of AT(1)-receptor blockers.Journal of human hypertension · 2002
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

K S LamDepartment of Medicine, University of Hong Kong, Queen Mary Hospital.
I K Cheng
E D Janus
R W Pang
Queen Mary Hospital · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury. We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus. Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin, an HMG CoA reductase inhibitor (n = 16; mean dose 30.0 +/- 12.6 mg/day) or placebo (n = 18) for 2 years. Renal function was assessed by serially measuring the serum creatinine, glomerular filtration rate (using Cr51-EDTA), and 24-h urinary protein excretion. Lovastatin treatment was associated with significant reductions in total cholesterol (p < 0.001), LDL-cholesterol (p < 0.001) and apo B (p < 0.01), the reductions at 24 months being 26, 30 and 18%, respectively. Beneficial effects on serum triglyceride, HDL-cholesterol and apo A1 levels were also observed. Lp(a) showed no significant change in both groups. Glomerular filtration rate deteriorated significantly in the placebo group after 24 months (p < 0.025) but showed no significant change in the lovastatin-treated patients. The increase in serum creatinine was statistically significant (p < 0.02) in placebo-treated patients at 12 and 24 months, and in the lovastatin group after 24 months. Twenty-four hour urinary protein excretion increased in both groups (p < 0.05). Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes. We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy.

Indexed as

Lipoprotein(a)Anticholesteremic AgentsApolipoprotein A-IApolipoproteinsApolipoproteins BApoprotein(a)Blood PressureBody Mass IndexCholesterolCholesterol, HDLCholesterol, LDLCreatinineDiabetes Mellitus, Type 2Diabetic NephropathiesDiet, DiabeticFemaleAnticholesteremic AgentsApolipoprotein A-IApolipoproteinsApolipoproteins BApoprotein(a)CholesterolCholesterol, HDLCholesterol, LDLCreatinineGlycated HemoglobinHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)LovastatinPlacebosTriglycerides

Identifiers

PMID7489845
OpenAlexW1995243968

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.